Form 4: Vertex Pharmaceuticals EVP, Chief Scientific Officer David Altshuler Reports Stock Sale

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the sale of 3,231 shares of common stock at $490 per share on March 3, 2025, under a pre-arranged trading plan.

Summary

• On March 3, 2025, David Altshuler, the EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 3,231 shares of common stock.
• The sale was executed at a price of $490 per share.
• Following the transaction, Altshuler directly owns 29,743 shares of Vertex Pharmaceuticals common stock.
• The transaction was made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on August 8, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of an insider stock sale under a pre-arranged trading plan. No indication of positive or negative implications for the company.

Industry Context

This is a routine disclosure of an insider stock sale. Such filings are common and provide transparency into the trading activities of company executives. It is important to note that the sale was conducted under a pre-arranged trading plan, which is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale by a high-ranking executive could be perceived negatively by some shareholders, although the pre-arranged trading plan mitigates this concern.

Key Dates